Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage by unknown
RESEARCH ARTICLE Open Access
Differential cytotoxicity induced by the
Titanium(IV)Salan complex Tc52 in G2-
phase independent of DNA damage
Theresa Pesch1, Harald Schuhwerk2,5, Philippe Wyrsch1, Timo Immel3,7, Wilhelm Dirks4, Alexander Bürkle2,
Thomas Huhn3 and Sascha Beneke1,6*
Abstract
Background: Chemotherapy is one of the major treatment modalities for cancer. Metal-based compounds such as
derivatives of cisplatin are in the front line of therapy against a subset of cancers, but their use is restricted by severe
side-effects and the induction of resistance in treated tumors. Subsequent research focused on development of
cytotoxic metal-complexes without cross-resistance to cisplatin and reduced side-effects. This led to the discovery of
first-generation titanium(IV)salan complexes, which reached clinical trials but lacked efficacy. New-generation titanium
(IV)salan-complexes show promising anti-tumor activity in mice, but their molecular mechanism of cytotoxicity is
completely unknown.
Methods: Four different human cell lines were analyzed in their responses to a toxic (Tc52) and a structurally highly
related but non-toxic (Tc53) titanium(IV)salan complex. Viability assays were used to reveal a suitable treatment range,
flow-cytometry analysis was performed to monitor the impact of dosage and treatment time on cell-cycle distribution
and cell death. Potential DNA strand break induction and crosslinking was investigated by immunostaining of damage
markers as well as automated fluorometric analysis of DNA unwinding. Changes in nuclear morphology were analyzed
by DAPI staining. Acidic beta-galactosidase activity together with morphological changes was monitored to detect
cellular senescence. Western blotting was used to analyze induction of pro-apoptotic markers such as activated
caspase7 and cleavage of PARP1, and general stress kinase p38.
Results: Here we show that the titanium(IV)salan Tc52 is effective in inducing cell death in the lower micromolar
range. Surprisingly, Tc52 does not target DNA contrary to expectations deduced from the reported activity of other
titanium complexes. Instead, Tc52 application interferes with progression from G2-phase into mitosis and induces
apoptotic cell death in tested tumor cells. Contrarily, human fibroblasts undergo senescence in a time and dose-
dependent manner. As deduced from fluorescence studies, the potential cellular target seems to be the cytoskeleton.
Conclusions: In summary, we could demonstrate in four different human cell lines that tumor cells were specifically
killed without induction of major cytotoxicity in non-tumorigenic cells. Absence of DNA damaging activity and the cell-
cycle block in G2 instead of mitosis makes Tc52 an attractive compound for further investigations in cancer treatment.
Keywords: Titanium(IV)salan complex, Apoptosis, Senescence, Cell-cycle, Tumorigenicity
* Correspondence: sascha.beneke@uni-konstanz.de
1University of Zurich, Institute of Veterinary Pharmacology and Toxicology,
8057 Zurich, Switzerland
6Present address: Department of Biology, University of Konstanz,
Ecotoxicology Group, 78457 Konstanz, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pesch et al. BMC Cancer  (2016) 16:469 
DOI 10.1186/s12885-016-2538-0
Background
Cancer is the second most frequent cause of death in in-
dustrial countries. Treatments to cure the disease range
from classical surgery, high-energy irradiation [1–3] or
DNA damaging drugs [4–9] and chemicals interfering
with DNA repair [10–12] to compounds tackling sig-
naling cascades [13–18] or the cytoskeleton [19–21]
and combinations thereof. One success story was the
discovery of cisplatin as chemotherapeutic agent [22].
Platinum-compounds still play a role in chemotherapy,
but their efficiency is limited to a minor cancer-panel and
hampered by severe side-effects and acquired resistance
[23]. Current research focuses on other metal-complexes,
with little cross-reactivity to cisplatin and reduced side-
effects. Several cytotoxic titanium-based complexes have
been investigated, with titanocene-dichloride and budoti-
tane reaching clinical trials [24–27]. Unfortunately, both
substances display a fast rate of hydrolysis [28], resulting
in low efficacy and cancelling of phase-II trials. Titaniu-
m(IV)salans displaying much longer half-life in aqueous
environments [29] and an antitumor-efficacy comparable
to cisplatin [29, 30], but with no cross-resistance [30].
Apoptosis induction by two differently substituted com-
plexes in tumor cell lines was described [29], and efficacy
was shown in a mouse tumor-model [31]. Titanium(IV)sa-
lans mode of action is unknown, but titanocene-dichloride
was enriched in chromatin regions [32], bound to DNA
and inhibited DNA-synthesis and topoisomerase II [33].
In order to elucidate the cytotoxic mechanism of titaniu-
m(IV)salans, we treated four different human cell lines
with the cytotoxic compound Tc52 [29] or the - despite a
high degree in structural identity - non-toxic Tc53 [34, 35]
(Additional file 1: Figure S1). We could not detect any
signs of DNA damage, but cytotoxicity was selective for
the tumorigenic cell lines investigated, accompanied by a
G2-phase cell-cycle block. Non-tumor cells were spared
from death, and fibroblasts underwent senescence. By
analyzing different mitosis-targeting toxins together with
Tc52, we could show that the putative target is the
cytoskeleton.
Results
DNA damage is not induced by Tc52
We investigated titanium-compounds Tc52 and Tc53 in
the well-established HeLa cancer cell line and in normal
VH7 fibroblasts. Both cell lines displayed similar sensi-
tivity in viability to Tc52 (EC50 and EC80 of 6 μM and
10 μM in HeLa, and of 3.5 μM and 10 μM in VH7, re-
spectively), whereas Tc53 had no effect (Additional file
2: Figure S2). This is interesting, as Tc53 has a very simi-
lar overall structure and differs from Tc52 only by the
exchange of four methyl-groups against tert-butyl groups.
Major impact of Tc52 was detected after 48 h incubation,
similar to published results [29]. As titanocene-dichloride
was reported to interact with DNA [33], we investigated
for direct or indirect induction of DNA-damage by Tc52.
We monitored for the appearance of DNA-break markers
poly(ADP-ribose) (PAR) and phosphorylation of histone
H2AX (γH2AX), using H2O2 as positive control
(Additional file 3: Figure S3A/B). Neither Tc52 (Fig. 1a/b)
nor Tc53 (data not shown) induced any DNA strand-
break marker up to 6 h of continuous treatment. However,
after 24 h a very small subset of HeLa cells displayed
γH2AX induction, coinciding with the onset of cell death.
Patterns of γH2AX formation in western-blots of HeLa
cell extracts after Tc52, Tc53 or H2O2 application
mirrored the results from immunofluorescence studies
(Additional file 3: Figure S3C). To detect DNA breaks and
crosslinks, we employed the sensitive automated FADU
and reverseFADU methods [36, 37]. Mitomycin C as
crosslinking agent showed the expected dose-dependent
fluorescence increase in reverseFADU (Fig. 1c), whereas
Tc53 (10 μM) was negative (Fig. 1d). In line with data
from immunofluorescence and western-blotting, 10 μM
Tc52 neither induced DNA-breaks nor crosslinks (Fig. 1e).
In summary, we could not detect any Tc52-dependent
DNA breakage or crosslinking activity.
Tc52 blocks cells in G2-phase
We performed flow-cytometry analyses of HeLa cells
after 30 h and 48 h of continuous treatment with differ-
ent Tc52 concentrations to monitor for potential inter-
ference with cell-cycle progression (Fig. 2, see Additional
file 4: Figure S4 for representative histograms). We
noticed a profound toxic effect (subG1-fraction, up to
30-fold induction) with increased concentration and in-
cubation time, accompanied by loss of G1-cells (2-fold).
At 2 μM and higher, G2/M content increased signifi-
cantly (1.5-fold), but dropped below control values at
10 μM. Tc53 had no impact on cell-cycle profile. As
Tc52-dependent G2/M-accumulation may have been the
result from interference in mitotic progression, we com-
bined Tc52 treatment with toxins blocking important
steps in mitosis and cytokinesis, i.e., actin-targeting cyto-
chalasin B (CytB) or tubulin-targeting colcemid (Col)
and docetaxel (Doc). To study potential interactions be-
tween Tc52 and the toxins, viability assays in HeLa were
performed using single agents or combinations with
6 μM Tc52 (EC50) for 24 h to reduce Tc52-dependent
cell death (Fig. 3). Under these conditions, Tc52 induced
a 23 % loss in viability. To analyze the interaction mode
of the combined compounds (antagonistic/additive/syn-
ergistic), we employed the algorithm of Chou and Tala-
lay [38]. As evident from Fig. 3a, cytotoxicity of CytB
and Tc52 was independent, leading to additive loss of
viability. Tc52 blocked toxicity at high concentrations of
tubulin-targeting Col and Doc (antagonistic), suggesting
that Tc52 may target the very same structure. We
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performed cell-cycle analysis in cells exposed to toxins
alone or in combination, i.e., 6 μM Tc52, 4 μM CytB,
27 nM Col and 50 nM Doc, respectively (Fig. 3b, see
Additional file 5: Figure S5 for representative histo-
grams). Tc52 treatment for 24 h did not change cell-
cycle profile, whereas Col-treated cells mildly accumulated
in G2/M (1.5-fold), which was more pronounced by CytB
(1.8-fold) and even further by docetaxel with more than
60 % in G2/M (2.9-fold). An increase of cells with a DNA
content >4 N was detected in CytB-treated cultures (5.3-
fold), most likely due to repressed cytokinesis, which leads
to formation of binuclear cells. Doc also induced this frac-
tion significantly (2-fold). All single treatments with CytB
(6.7-fold), Col (12.3-fold) or Doc (16.9-fold) induced a
subG1 peak, an indicator of cell death, and a reduction in
G1 cell count (28.8-fold, 1.5-fold, and 23.2-fold, respect-
ively) Tc52 addition reduced the percentage of cells with
>4 N in Tc52-docetaxel samples compared to Doc alone
(1.6-fold of control). The increase of cells with >4 N in-
duced by CytB was severely decreased by 50 % with a con-
comitant increase in G2/M- and subG1-fractions (2.5-fold
and 9.2-fold compared to control, respectively). To dis-
criminate between mitosis and G2-phase, we treated cells
as above and determined the mitotic index (MI) (Fig. 3c).
As expected, Col and Doc caused an increase in MI by
twofold and more than 11-fold, respectively. In contrast,
CytB reduced MI more than threefold. Tc52 treatment
alone induced a complete absence of mitotic figures.
Combination of Tc52 with the toxins severely reduced the
MI below normal control values, which indicates that
Tc52 acts in advance of Col or Doc. To monitor the im-
pact of Tc52 on cytoskeletal organization, we performed
immunofluorescence co-staining for tubulin and actin
(Fig. 3d). As expected, CytB induced binuclear cells (aster-
isk) with normal tubulin network, and actin was partially
aggregated as detected by phalloidin-staining. Col blocked
metaphases (closed arrow) with impaired mitotic spindles
and normal actin network. Doc induced multipolar spin-
dles in cells arrested in mitosis (closed arrow), and lobed
nuclei in cells escaping it. Tubulin was strongly stained
and arranged as straight fibers. Tc52-treated cells dis-
played slightly diminished phalloidin-staining with gran-
ules, and tubulin bundles in cellular protrusions (open
arrows). Co-treatments showed deranged actin and tubu-
lin networks. Induction of binuclear cells by CytB, meta-
phase arrest by Col, or fixed mitosis/lobed nuclei by Doc
were no longer detectable when Tc52 was co-applied as
expected. In summary, this indicates that Tc52 interferes
with a step before progression into mitosis, i.e., during
G2-phase.
Tc52 induces apoptosis in cancer cells and senescence in
fibroblasts
In a next step, we investigated whether Tc52 pulse-
treatment might be sufficient to induce these effects
(Fig. 4). We incubated HeLa and VH7 for 6 h with in-
creasing Tc52 concentrations and analyzed after 30 h the
cell-cycle distribution by flow-cytometry. Whereas HeLa
displayed major cytotoxicity at 10 μM with a loss of G1-
cells (3-fold), fibroblasts showed no cell death as indi-
cated by an unchanged subG1-fraction. Instead, cells in
G1 gradually decreased (1.4-fold) concomitant with an
accumulation in G2/M (1.5-fold) (Fig. 4a/b, see
Additional file 6: Figure S6 for representative histo-
grams), suggesting a differential response to Tc52 in
tumorigenic HeLa and untransformed VH7 fibroblasts.
To analyze this in more detail, HeLa and VH7 were
treated for 2 h, 6 h, or 30 h with 2 μM or 10 μM Tc52
and nuclei were monitored for apoptosis or other alter-
ations after a total of 30 h (Fig. 4c-f). HeLa displayed
after the 2 h exposure to 10 μM Tc52 a sevenfold in-
crease in apoptotic figures (Fig. 4c/e), which doubled
(See figure on previous page.)
Fig. 1 Tc52 does not induce DNA damage. a: Detection of PAR (upper panel) and γH2AX (lower panel) by immunofluorescence after application of
10 μM Tc52 in HeLa cells. For positive controls (+), cells were incubated with 500 μM H2O2 for 10 min (PAR detection) and for 6 h (γH2AX detection).
Respective upper rows show staining of nuclei (DAPI), lower rows detection of either PAR or γH2AX. Incubation time is depicted between both panels.
γH2AX is only evident in apoptotic cells after 24 h. For each independent experiment, at least 100 cells were analyzed in technical duplicates. b Detection
of PAR (upper panel) and γH2AX (lower panel) by immunofluorescence after application of 10 μM Tc52 in VH7 normal fibroblasts. For positive controls (+),
cells were incubated with 500 μM H2O2 for 30 min (PAR detection) and for 1 h (γH2AX detection). Respective upper rows show staining of nuclei (DAPI),
lower rows detection of either PAR or γH2AX. Incubation time is depicted between both panels. For each independent experiment, at least 100 cells were
analyzed in technical duplicates. Complete time course of H2O2 treatment is depicted in Additional Fig. 3a for HeLa cells and Additional Fig. 3b for VH7
fibroblasts. c: Dose–response curve for mitomycin C-dependent crosslinking in HeLa. Bars indicate fluorescence signals with (filled bars) or without (open
bars) 25 Gy irradiation as detected by FADU. Irradiation reduces, application of mitomycin C increases signals. Asterisks (*) indicate significant difference
between irradiated and non-irradiated samples; hashtags (#) describe significance compared to the respective controls (0). p< 0.05 = #/*, p< 0.01 = ##/**;
p< 0.001 = ###/***, (two-way ANOVA, Sidak's Multiple Comparison Test). At 100 μM mitomycin C, strong crosslinking prevents drop in signal intensity by
irradiation. d: Time course of DNA breaks and crosslink detection by FADU after application of 10 μM Tc52 to HeLa cells for the indicated time points. Bars
indicate fluorescence signals with (filled bars) or without (open bars) 25 Gy irradiation as detected by FADU. No change in signal intensity over time can be
observed. 50 μg/ml mitomycinC (MMC) was applied as positive control. e: Time course of DNA breaks and crosslink detection by FADU after application of
10 μM Tc53 to HeLa cells for the indicated time points. Bars indicate fluorescence signals with (filled bars) or without (open bars) 25 Gy irradiation as
detected by FADU. No change in signal intensity over time can be observed. 50 μg/ml mitomycinC (MMC) was applied as positive control
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with prolonged treatment, but no additional changes in
nuclear morphology. VH7 displayed only at 30 h of
10 μM Tc52 a minor increase in apoptotic cells (Fig. 4d/
f ). In contrast, chromatin in VH7 nuclei structurally
changed and DAPI-dense regions appeared, dependent
on Tc52 concentration and exposure time (Fig. 4g).
These foci very much resembled senescence associ-
ated heterochromatic foci (SAHF) [39, 40], which are
indicators of cellular senescence. To further investi-
gate on this, we analyzed senescence-associated beta-
galactosidase (SAβGal)-activity, an enzymatic hallmark of
senescence [40, 41]. Using the same pulse-treatment setup
as before, we observed a time- and dose-dependent cell-
enlargement, accompanied by increasing SAβGal-activity
(Fig. 5a). Tc53-treated cells were undistinguishable from
controls. There was a clear gain in positive staining with
time and concentration of Tc52 (Fig. 5b). These results
provide solid evidence that Tc52 induces senescence in fi-
broblasts. To support our observations about cell-specific
toxicity of Tc52 by an alternative approach, we employed
a recently established method to analyze cytotoxic-
potential of compounds by measuring changes in free
cytosolic Ca2+-levels by Fluo4-NW-dye [42]. We exposed
HeLa and VH7 to 2 μM or 10 μM Tc52 or 10 μM Tc53,
and monitored for increased free cytosolic Ca2+
(Additional file 7: Figure S7, for methods see Additional
file 8). In line with the cell-cycle and DAPI analysis, HeLa
displayed a rapid increase in Ca2+-dependent fluorescence
at both Tc52 concentrations (Δ4-RFU and Δ5.5-RFU after
5 s/ Δ6.5-RFU and Δ5-RFU after 10 s, respectively). In
contrast, free Ca2+ in VH7 increased only marginally and
very transient over control at 10 μM (Δ1.1-RFU after 5 s,
Δ0-RFU after 10 s). 10 μM Tc53 was indistinguishable
from controls. To strengthen our observation of cell-
line specific response in toxicity, we treated cultures
with Tc52 or Tc53 for 30 h and analyzed phosphoryl-
ation of the stress-associated p38 MAP-kinase (p-p38)
and the appearance of cleaved caspase7, a sign for
ongoing apoptosis. Both HeLa and VH7 showed an
elevation in p-p38, but only HeLa displayed pro-
nounced induction of active caspase7 (Fig. 6a-d),
whereas Tc53 induced neither p-p38 nor caspase7-
cleavage (Additional file 9: Figure S8). To validate
these data, we monitored the cleavage of poly(ADP-ri-
bose) polymerase1 (PARP1), a well-established event
in early execution phase [43, 44]. Apoptotic PARP1
85 kDa-fragment was significantly induced in HeLa,
but not in VH7 fibroblasts (Fig. 6). Identical
response-patterns were observed in U2OS cancer cells
and low-passage HEK293 (Fig. 7), with the latter be-
ing immortal but non-tumorigenic [45]. Viability loss
induced by Tc52 was similar compared to HeLa or
VH7, with EC50 values of 2 μM (U2OS) and 4 μM
(HEK293) (Additional file 10: Figure S9). In both cell
lines p-p38 increased in a dose- and time-dependent
manner, but only U2OS cells displayed activation of
caspase7 and PARP1-cleavage (Fig. 7). In summary,
Tc52 induced a p-p38 related stress signaling in all
cell lines, but only cancer cells responded with
apoptosis.
Fig. 2 Dose-dependent changes in cell-cycle profile by Tc52. a: Cell-
cycle distribution of HeLa cells after 30 h incubation with increasing
concentrations of Tc52. Filled bars: G1; open bars: S; hatched bars: G2/
M; vertical line bars: subG1. Dose-dependent increase (30-fold) in subG1
from 1 μM to 10 μM with significant decrease in G1 starting at 5 μM (2-
fold), the latter accompanied by accumulation in G2/M (1.5-fold). Tc53
has no impact on cell-cycle distribution. b: Cell-cycle distribution of
HeLa cells after 48 h incubation with increasing concentrations of Tc52.
Filled bars: G1; Pointed bars: S; Hatched bars: G2/M; Open bars: subG1.
Dose-dependent increase (44-fold) in subG1 from 1 μM to 10 μM
concomitant with significant decrease in G1 (2.7-fold), accompanied by
fluctual accumulation in G2/M. Tc53 has no impact on cell-cycle
distribution. Treatments were compared to controls and significance
was calculated by two-way ANOVA with Dunnett's Multiple
Comparison Test. p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***
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Discussion
Efficacy of cancer treatment relies on higher sensitivity
of tumor cells towards chemotherapeutic agents com-
pared to surrounding tissue. The search for metal-based
chemotherapeutics other than cisplatin-derivatives led to
the discovery of titanium as potential replacement, with
titanocene-dichloride and budotitane reaching clinical
trials. Unfortunately, both compounds lacked anti-
tumorigenic potential due to rapid hydrolysis in aqueous
solutions [28]. Titanium(IV)salans are much more stable
[29] and have been shown to display promising activity
against cancer cells in vitro as well as in mouse models,
including some selectivity for tumor cells [30]. But the
underlying mechanism of cytotoxicity and the cellular
targets have not been defined yet. We investigated this
for the toxic titanium(IV)salan Tc52 and the non-toxic
Tc53, which display a high degree of structural similarity
with only small variations, in different human cell lines.
Viability was similarly affected by Tc52 in all lines ana-
lyzed, with EC50 values between 2 μM and 6 μM Tc52
(Additional file 2: Figure S2 and Additional file 10: Fig-
ure S9), whereas Tc53 had no impact. This discrepancy
in toxicity cannot be attributed to differential uptake, as
similar timing in cellular accumulation has been re-
ported for related titanium(IV)complexes [46]. Import-
antly, viability assays do not discriminate between
cytotoxic and cytostatic effects, as in both cases cell
numbers are reduced compared to controls. Deduced
from titanocene-dichloride [33], we expected genomic
DNA to be the target of Tc52. We monitored for DNA
strand-break induction with a variety of different assays,
using the very sensitive FADU and reverseFADU method
able to detect strand-breaks induced by 0.13 Gy of X-ray
[36] as well as DNA crosslinks [37], respectively, and
checked for the appearance of the two different damage
markers PAR and γH2AX. Whereas synthesis of PAR is
an early marker for DNA strand-breaks, detectable
within seconds to minutes [47], γH2AX foci appear later
and correlate finally with the amount of double-strand
breaks [48]. We failed to observe any DNA damage in-
duction (Fig. 1) after Tc52 application in contrast to
H2O2 treatment (Additional file 3: Figure S3). These data
exclude that nuclear DNA is targeted by Tc52. Analyzing
the cell-cycle profile of HeLa after Tc52 treatment re-
vealed major cell death induction concomitant with a
transient block in G2/M-phase (Fig. 2). A reasonable ex-
planation could be that Tc52 interferes with a step dur-
ing mitosis or cytokinesis, similar to biological toxins
such as cytochalasin B from fungi, colchicine from
autumn crocus or taxanes from yew. CytB induces
binuclear cells as it interferes with formation of the
contractile actin-ring in cytokinesis. In contrast, the
(See figure on previous page.)
Fig. 3 Tc52 blocks cells in G2 and alters tubulin network. Treatment of HeLa tumor cells with toxins targeting different steps in M-phase in combination
with Tc52. M-phase drugs were administered in increasing concentrations either alone or together with 6 μM Tc52 (EC50) for 24 h. a: Viability assays from
treatments with cytochalasin B (CytB), colcemid (Col) or docetaxel (Doc) alone and in combination with 6 μM Tc52. Tc52 itself reduced viability to
77.1 % +/− 1.78 SEM. Tc52 together with CytB displays additive toxicity to CytB alone (parallel curves), whereas Tc52 acts protective in combination with
high doses of Col or Doc, as evident from the Combination Index calculated by the algorithm of Chou and Talalay [38] (last panel, Col +/− 0.023 SEM,
Doc +/− 0.032 SEM, compared to hypothetical value 1). b: Cell-cycle analysis of single and combinatory treatments after 24 h application of 4 μM
cytochalasin B (CytB), 27 nM colcemid (Col) and 50 nM docetaxel (Doc) alone or in combination with 6 μM Tc52. Single treatments were compared to
control or to the respective combination. Significance was calculated by two-way ANOVA with Dunnett's Multiple Comparison Test p < 0.05 = *, p <
0.01 = **, p < 0.001 = *** for comparison of treatments to control, and with two-tailed T-test between single and double treatments. Tc52 has no impact
on cell-cycle profile, Col increases number of cells in G2/M (1.5-fold), accompanied by a drop in G1 (1.5-fold). This is more pronounced with CytB (1.8-
fold and 28.8-fold, respectively) or Doc (2.3-fold and 23.3-fold, respectively). Cells in S-phase are significantly reduced, 6-fold with CytB and 3.6-fold with
Doc. SubG1 is increased for Col (12.4-fold), CytB (6.8-fold) and Doc (17-fold). Tc52 addition does not change cell-cycle profile of Col treatment, but
reduces number of cells with >4 N content in CytB and Doc treated samples 1.8-fold and 1.3-fold compared to single treatments, respectively. G2/M
content and SubG1 are increased only compared to CytB treatment 1.4-fold and 1.3-fold, respectively. Filled bars: G1; Open bars: S; Hatched bars: G2/M;
Pointed bars >4 N; Vertical line bars: subG1. c: Cells were treated for 24 h with toxins as in 3b, fixed with formaldehyde and analyzed by DAPI staining
for the presence of mitotic figures. 100 cells/experiment were evaluated (in docetaxel-treated samples only 50 cells/experiment) in independent
triplicates. The percentage of mitotic cells (Mitotic Index, MI) was calculated and values compared to control (*). In addition, double treated samples
were compared to single treatments (+). Significance was calculated by two-tailed T-test, p < 0.01 = **/++, p < 0.001 = ***/+++. CytB reduced MI 3.6-fold,
Col and Doc enhanced MI 2.1-fold and 11.4-fold, respectively. Tc52 severely reduces MI in all cases. d: Immunofluorescence analysis of actin and tubulin
in drug-treated HeLa cells. Cells were treated and fixed as described in 3c. Tubulin was detected by indirect immunofluorescence whereas f-actin was
directly detected by Atto488-coupled phalloidin. Control cells (Ctr) show normal mitosis (filled arrow) and proper actin and tubulin network. Tc52-
treated samples display changes in cell morphology such as tubulin bundles at the cell periphery (open arrow) and alterations of f-actin pattern.
Cytochalasin B (CytB) changes actin distribution, inducing either aggregation or dim f-actin staining as well as binuclear cells (asterisk). Tubulin is
unaffected. Double treated samples (Tc52/CytB) show a combination of changes in f-actin as well as tubulin networks (open arrow), but lack bi-nuclear
cells. Colcemid-treated cells (Col) display improper mitotic spindle formation and cells blocked in metaphase (filled arrow). Double treated samples
(Tc52/Col) are free of mitotic figures and display altered tubulin network (open arrow). Docetaxel (Doc) induces high levels of mitotic cells (filled arrow)
and lobed nuclei, accompanied by strong staining of short tubulin fibers and mitotic spindles. As cells are blocked in mitosis, it was not possible to
evaluated changes in the actin network. Double treated samples (Tc52/Doc) completely lack mitoses, and arrangement of tubulin fibers is improved
and cells display proper actin network
Pesch et al. BMC Cancer  (2016) 16:469 Page 7 of 16
Fig. 4 (See legend on next page.)
Pesch et al. BMC Cancer  (2016) 16:469 Page 8 of 16
colchicine-derivate colcemid or the taxane docetaxel tar-
get tubulin, leading to metaphase arrest, but whereas
Col prevents tubulin polymerization, Doc blocks disas-
sembly of tubulin. As a consequence of taxane
treatment, multipolar spindles are induced, and cells es-
caping mitotic block show characteristic lobed or frag-
mented nuclei [49]. Tc52 was applied in combination
with all three compounds. Tc52 toxicity was additive to
CytB in viability assays, but protected from cytotoxicity
of higher doses of Col and Doc (Fig. 3a). Whereas
addition of Tc52 mildly changed cell-cycle profile of Col
and Doc treated samples, the percent of cells containing
>4 N DNA content, i.e., binucleated cells, was drastically
reduced in CytB/Tc52-treated cells (Fig. 3b). DAPI-
staining of nuclei revealed that addition of Tc52 led to a
severe drop in mitotic index (Fig. 3c). In concert with the
cell-cycle analysis, these data indicate that Tc52 is not af-
fecting mitosis, but targets an unknown step in G2, pre-
venting progression into M-phase. We hypothesize that
steps before or at G2-M transition as centrosome-
separation, kinase-signaling or the cytoskeleton might be
affected. Interestingly, it has been reported that tubulin
targeting colcemid has two different modes of action: At
low doses it inhibits proper plus-end dynamics and im-
pacts on cell migration, whereas at high doses it seems to
induce cell death by microtubule fragmentation during
mitosis [50]. Indeed, visualization of tubulin and F-actin
indicated that Tc52 induced small alterations in the tubu-
lin network, displaying increased bundling at the cellular
periphery also in combination with other toxins (Fig. 3d).
Whether Tc52 also impacts on migration needs to be de-
termined in future research. But probably Tc52 acts
independent of this as treated cells are blocked in a step
before condensation of chromosomes takes place and mi-
totic microtubules are formed. Actin was mildly affected
by Tc52, which could be due to modified tubulin function-
ality. F-actin staining was severely affected by CytB as
expected, reshuffling actin into bright foci without
network-formation. Col and Doc affected only the tubulin
network. Of note, combined Doc/Tc52 treatment "res-
cued" actin and tubulin network compared to Doc-only
treated samples, which supports the idea of acting in ad-
vance of Doc and thus mitosis. In summary, the protec-
tion from Col- and Doc-dependent cytotoxicity, together
with the cell-cycle analysis and data from immunofluores-
cence suggests that Tc52 acts on the same pathway as Col
or Doc, but independent of actin-targeting CytB. Monitor-
ing cell-cycle distribution after Tc52 pulse-treatment of
HeLa and VH7 revealed massive apoptosis-induction in
tumorigenic HeLa, whereas fibroblasts were blocked in
G2/M without signs of cell death (Fig. 4a/b). Appearance
of apoptotic figures in HeLa confirmed the time- and
dose-dependent increase in toxicity by Tc52 (Fig. 4c/e),
which was absent in VH7 as expected from cell-cycle data
(Fig. 4d/f). Instead, VH7 nuclei displayed changes in chro-
matin structure, i.e., an increase of DAPI-dense foci
resembling SAHF [39, 40] (Fig. 4d/g), together with char-
acteristic morphological changes such as enlargement and
flattening (Fig. 5). Testing for SAβGal activity confirmed a
time- and concentration-dependent induction of senes-
cence (Fig. 5). To support our findings, we analyzed the
rapid release of free Ca2+ in the cytosol in HeLa and VH7
after Tc52 exposure. This method was developed to
quickly determine the cytotoxic potential of a substance
(See figure on previous page.)
Fig. 4 Tc52 induces apoptosis in HeLa but not in VH7 fibroblasts. HeLa and VH7 cells were exposed to three different Tc52 concentrations (2 μM, 5 μM,
10 μM) and 10 μM Tc53 for indicated time points, followed by incubation in toxin-free medium. Treatments were compared to controls and significance
was calculated by two-way ANOVA with Dunnett's Multiple Comparison Test, p < 0.05 = *, p < 0.01 = **; p < 0.001 = ***. Significance between different
time-points was calculated by one-way ANOVA with Tukey-Kramer Multiple Comparisons Test, p < 0.01 = ##; p < 0.001 = ###. a: Cell-cycle distribution of
HeLa cells after 6 h Tc52 treatment and 24 h release reveals major increase in the subG1 fraction at 10 μM Tc52 (8.7-fold, accompanied by a loss of cells
in G1 (3-fold). Tc53 has no effect. b: Cell-cycle distribution of VH7 after 6 h Tc52 treatment and 24 h release reveals accumulation in G2/M and increased
>4 N-fraction accompanied by loss from G1 without increase in subG1 at 5 μM (1.5-fold G2/M, 1.4-fold >4 N, 1.5-fold G1) and 10 μM (1.3-fold G2/M, 1.5-
fold >4 N, 1.3-fold G1) Tc52. Tc53 has no effect. c: Representative pictures of HeLa cells displaying dose- and time-dependent appearance of apoptotic
figures (open arrows). Cells were treated with 2 μM or 10 μM Tc52 for 2 h, 6 h, or 30 h, washed, fixed with formaldehyde and nuclei were stained with
DAPI. d: Representative pictures of normal VH7 fibroblasts displaying a dose- and time-dependent alteration of the nuclear structure, forming DAPI-rich
foci (filled arrows). Cells were treated with 2 μM or 10 μM Tc52 for 2 h, 6 h, or 30 h, washed, fixed with formaldehyde and nuclei were stained with DAPI.
e: Statistical evaluation of number apoptotic figures in HeLa cells from three independent experiments counting at least 100 cells each. Significant
apoptosis induction compared to control (2.3 %) is detected in 10 μM Tc52 samples treated for 2 h (16.4 %) and rate increases with exposure to 6 h
(30.6 % at 6 h and 30.5 % at 30 h). Significance of increase compared to control was analyzed by two-way ANOVA and Dunnett’s Multiple Comparison
test (*), and differences between 10 μM treatments were calculated by one-way ANOVA and Tukey’s Multiple Comparison Test (#). f: Statistical evaluation
of apoptotic figures in VH7 cells from three independent experiments counting at least 100 cells each. Significant increase in apoptotic cells compared
to controls (2.2 %) is only detected in cultures exposed to 10 μM Tc52 for the complete 30 h (15.5 %). Significance of increase compared to control was
analyzed by two-way ANOVA and Dunnett’s Multiple Comparison test (*), and differences between 10 μM treatment was calculated by one-way ANOVA
and Tukey’s Multiple Comparison Test (#). g: Statistical evaluation of VH7 cells nuclei containing DAPI-rich foci. Foci were graded regarding their intensity
over the nuclear DAPI background from three independent experiments counting at least 100 cells each. There is a clear dose- and time-dependent
increase in the number of cells displaying DAPI-bright foci with a shift from low-grade to high-grade foci. Significance was calculated by two-way
ANOVA and Dunnett’s Multiple Comparison Test (*)
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[42]. Both low and high concentrations induced in HeLa a
strong increase in Ca2+-dependent fluorescence, which
was absent in fibroblasts (Additional file 7: Figure S7),
supporting the cell-specific difference in Tc52 response.
Activation of the general stress-kinase p38 by phosphoryl-
ation at T180/Y182 is central to many cell fate pathways
such as cell death, senescence, differentiation and tumori-
genesis (reviewed in [51]). In order to analyze whether
Tc52 and Tc53 application leads to activation of p38, we
probed for total and phosphorylated p38 in four cell lines.
Indeed, Tc52 led to increased p-p38 in a time and dose-
dependent manner in all of them (Figs. 6, 7). In contrast,
non-cytotoxic Tc53 did not show enhanced p-p38 levels
(Additional file 8: Figure S8). To confirm the observed dif-
ferential impact of Tc52 on cell death, we probed for
apoptosis-dependent cleavage of caspase7 [52]. Indeed,
only HeLa and U2OS displayed dose- and time-dependent
activation of caspase7 (Figs. 6, 7), and Tc53 was without
effect (Additional file 9: Figure S8). Supporting our data,
apoptotic PARP1-cleavage was evident only in HeLa and
U2OS cultures treated with Tc52, but not in VH7 and
HEK293 (Figs. 6, 7).
In summary, the titanium(IV)salan Tc52 is effective
with an EC50 value in the low-micromolar range. Tc52
interferes with cell-cycle progression in G2 and deduced
from our data, tubulin-related signaling is targeted, as
Tc52 treatment induces alterations in the tubulin
network and partially rescues from cytotoxicity of
tubulin-interacting toxins that induce mitotic arrest. Al-
ternatively, Tc52 may interfere with centrosomal regula-
tion and prevent in this way entry into mitosis, but this
would not explain the differential response towards
combination with actin- or tubulin-targeting toxins. The
actual target of Tc52 has to be elucidated in future
Fig. 5 Tc52 induces senescence in VH7 fibroblasts. VH7 fibroblasts were treated as indicated in Fig. 4, including an additional 5 μM Tc52
concentration, for measuring SAβGal-activity. There is a clear increase in cells with active SAβGal as well as changes in cellular morphology, i.e.,
enlargement and flattening (panel a, black arrows). Lower panel b displays evaluation of SAβGal-activity. There is a significant dose- and time-
dependent increase in SAβGal-activity per cell. Different doses at one time-point were compared and significance was calculated by one-way
ANOVA with Bonferroni Multiple Comparison Test (#). Significant dose-dependency is detected at all time points except for 30 h, which shows dif-
ference between 2 μM and 5 μM or 10 μM, but not between 5 μM and 10 μM Tc52. Individual doses over time were compared to controls and
significance was calculated by one-way ANOVA with Dunnett's Multiple Comparison Test, p < 0.01 = **
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research. Nevertheless, as a consequence tumor cells re-
spond with apoptotic death, whereas normal fibroblasts
show induction of senescence. We hypothesize that the
constant block in G2 imposed by Tc52 cannot be han-
dled properly by tumor cells, leading to induction of
apoptosis.
Conclusions
We provided several layers of evidence for the differen-
tial cytotoxic potential of the titanium(IV)salan Tc52 by
a pathway that is not affecting genomic integrity. As
proof-of-principle, we compared two well-established
cancer cell lines, HeLa and U2OS, with VH7 fibroblasts
Fig. 6 Activation of p38 stress-kinase, caspase7 and PARP1 cleavage by Tc52 in HeLa and VH7 fibroblasts. Treatment regimen was as described
for Fig. 4. Ctr: solvent treated samples, +: positive control. Shown below each incubation time (2 h, 6 h, 30 h) are the different Tc52 concentrations
used, i.e., 2 μM, 5 μM, and 10 μM. For statistical analysis, ratio of ECL signals of target protein compared to the respective loading control was
calculated. Significant changes compared to solvent-control were analyzed by two-way ANOVA with Dunnett's Multiple Comparison Test, p < 0.05 = *;
p < 0.01 = **; p < 0.001 = ***. a: Respective western blot panel for HeLa cells, displaying levels of phosphorylated p38 (p-p38) stress kinase, total p38
(p38), α-tubulin, cleaved caspase7, GAPDH, PARP1 and 85-kDa apoptotic fragment (arrow), and β-actin. b: Respective western blot panel for VH7
fibroblasts, displaying levels of phosphorylated p38 (p-p38) stress kinase, total p38 (p38), α-tubulin, cleaved caspase7, GAPDH, PARP1 and 85-kDa apoptotic
fragment (arrow), and β-actin. c: Evaluation of stress-response in HeLa cells from at least three independent experiments. Panels display ratios of p-p38/p38,
cleaved caspase7/GAPDH and PARP1 85 kDa/total, which all increase significantly in a time- and dose-dependent manner. d: Evaluation of stress-response
in VH7 fibroblasts from at least three independent experiments. Panels display ratios of p-p38/p38, cleaved caspase7/GAPDH and PARP1 85 kDa/total. Only
p38-dependent stress response increases significantly in a time- and dose-dependent manner without any signs of apoptotic alterations (cleavage of
caspase7 or PARP1)
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and low-passage HEK293. Importantly, Tc52 does not
target DNA or block progression through mitosis, which
maintains genomic information and stability. In this
way, there is no risk of inducing mutations in normal
tissue, which may lead to the outgrowth of secondary tu-
mors after cancer therapy [53]. P38 stress kinase is
activated in all cells, but only tumor cell lines responded
with cell death as evidenced by caspase7 activation and
PARP1-cleavage. Supporting this, HeLa cells treated
with Tc52 displayed an increase in subG1-fraction,
apoptotic figures and cytosolic Ca2+, but not human
fibroblasts, which showed induction of senescence.
Fig. 7 Activation of p38 stress-kinase, caspase7 and PARP1 cleavage by Tc52 in U2OS and HEK293. Treatment regimen was as described for Fig. 4. Ctr:
solvent treated samples, +: positive control. Shown below each incubation time (2 h, 6 h, 30 h) are the different Tc52 concentrations used, i.e., 2 μM,
5 μM, and 10 μM. For statistical analysis, ratio of ECL signals of target protein compared to the respective loading control was calculated. Significant
changes compared to solvent-control were analyzed by two-way ANOVA with Dunnett's Multiple Comparison Test, p< 0.05 = *; p < 0.01 = **; p< 0.001
= ***. a: Respective western blot panel for U2OS cells, displaying levels of phosphorylated p38 (p-p38) stress kinase, total p38 (p38), α-tubulin, cleaved
caspase7, GAPDH, PARP1 and 85-kDa apoptotic fragment (arrow), and β-actin. b: Respective western blot panel for HEK293 cells, displaying levels of
phosphorylated p38 (p-p38) stress kinase, total p38 (p38), α-tubulin, cleaved caspase7, GAPDH, PARP1 and 85-kDa apoptotic fragment (arrow), and β-
actin. c: Evaluation of stress-response in U2OS cells from at least three independent experiments. Panels display ratios of p-p38/p38, cleaved caspase7/
GAPDH and PARP1 85 kDa/total, which all increase significantly in a time- and dose-dependent manner. d: Evaluation of stress-response in HEK293 from
at least three independent experiments. Panels display ratios of p-p38/p38, cleaved caspase7/GAPDH and PARP1 85 kDa/total. Only p38-dependent stress
response increases significantly in a time- and dose-dependent manner without any signs of apoptotic alterations (cleavage of caspase7 or PARP1)
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Further exploration of the potential anti-tumorigenic
effect of this new titanium(IV)salan could be of great
clinical benefit. If chemotherapy would actually dis-
criminate between tumor and normal cells, fighting
cancer could be far more effective.
Methods
Cell culture and toxins
Cells were cultured in DMEM-GlutaMax (Life-Tech-
nologies)/10 % FCS/1 % PenStrep (Life-Technologies).
VH7 normal fibroblasts were used from passage 20–30,
HEK293 from passage 24–34, HeLa and U2OS from
routine culture. Authentication of cell lines was per-
formed by short tandem repeat (STR) DNA-typing.
Toxins were applied in medium at the concentrations
and for the time periods specified with appropriate solvent
controls in parallel. DMSO concentrations in medium were
either 0.2 % (titanium(IV)salans alone) or 0.3 % in combin-
ation treatments. Titanium(IV)salans (Chemistry-Depart-
ment University of Konstanz), cytochalasinB (Sigma) and
docetaxel (LC-Laboratories) were solubilized in DMSO,
colcemid (KaryoMax, Life-Technologies) and H2O2 (Sigma)
diluted in medium.
Viability assay
Cells were seeded into 96well-plates (clear bottom/white
walls, Corning) and grown for 24 h. Medium was ex-
changed against medium containing toxins and incu-
bated for 24 h or 48 h. Supernatant was replaced with
fresh medium containing 9 μg/ml resazurin (Sigma) and
incubated until medium in control wells turned purple.
Fluorescence (excitation/emission 560 nm/590 nm) was
measured using LS55-spectrometer (Perkin-Elmer). Each
experiment was performed in technical duplicates or
triplicates.
Immunofluorescence
Cells were seeded 24 h in advance onto glass cover-slips.
Medium was supplemented with the respective toxin
and incubated for the times specified. Cells were fixed
with 3.7 % formaldehyde/PBS for 20 min at room
temperature (RT), washed 1x with 0.1 M glycine/PBS for
3 min at RT and permeabilized for 5 min at RT in 0.4 %
TritonX100/TBS except for detection of PAR. For PAR,
cells were fixed by incubation for 7 min in −20 °C
methanol at 4 °C. Subsequent procedures were identical.
After three washes with TBS, cells were blocked in TBS/
0.3 % Tween 20/1 % BSA for 30 min at 37 °C and incu-
bated for 1 h at 37 °C with 1.antibody diluted in
blocking-solution, followed by three washes for 10 min
at RT in TBS/0.3 % Tween 20. 2.antibody incubation
was performed for 1 h at 37 °C in blocking-solution,
followed by three washes as above. Nuclei were stained
with 20 ng/ml DAPI-solution, air-dried and mounted
with AquaPolymount (PolySciences). Epifluorescence
pictures were taken using a Nikon-EclipseTS100 micro-
scope and NIS-ElementsD3.2 software. Subsequent
analysis was performed using ImageJv1.47n and CS-
Photoshop5.
Antibodies: 10H anti-PAR [54], anti-γH2AX (Millipore),
anti-αTubulin (Sigma), goat-anti-mouse Alexa594 (Mo-
lecular Probes, Invitrogen). Phalloidin-Atto488 anti-F-
actin (Sigma) was solubilized in DMSO to 40 μM and
further diluted to 400 nM.
Automated FADU and reverseFADU
Methods have been described in detail in [36, 37].
Briefly, cells were seeded 24 h before toxin treatment.
After incubation with respective concentrations of mito-
mycinC, 10 μM Tc52 or Tc53 for the indicated times,
cells were harvested and analyzed for strand-breaks by
FADU or in parallel for crosslinks by reverseFADU. For
reverseFADU, cells were additionally irradiated with
25 Gy X-rays before FADU procedure. Liquid handling
was performed on a Genesis RSP100 robot (Tecan).
Cells were lysed and unwinding of DNA was induced by
alkaline conditions. After neutralization, the relative
amount of double-stranded DNA in each sample was
measured by SYBR-Green fluorescence (excitation/emis-
sion 492 nm/520 nm) in FLx800-fluorescence microplate-
reader (Bio-TEK Company).
Cell-cycle analysis
Cells were seeded on 10 cm-dishes and incubated for
24 h. Medium was replaced with medium containing re-
spective toxins and incubated for the time periods indi-
cated. In samples exposed for 6 h, medium was replaced
with fresh standard medium and further incubated for
24 h. Floating cells were collected, combined with adher-
ent cells harvested by trypsin, and pelleted by centrifuga-
tion. Cells were washed twice with ice-cold PBS, fixed by
resuspending in ice-cold 70 % ethanol to a concentration
of 1x106 cells/ml and stored at −20 °C. For analysis,
fixed cells were pelleted by centrifugation and washed
once with PBS. Pellets were suspended in PBS contain-
ing 100 μg/ml RNaseA and 25 μg/ml propidium iodide
to 1x106 cells/ml. Cell-cycle distribution was monitored
using FACSCantoII (BD-Biosciences) and about 10000
events were counted in each single run. Subsequent ana-
lysis was performed using Flowing-Software2.1.
SAβGal activity assay
The SAβGal-kit from Cell-Signaling was used following
manufacturer's instructions. VH7 were seeded into
6well-plates and incubated for 24 h. Afterwards, medium
was exchanged against medium containing Tc52 at con-
centrations of 2 μM/5 μM/10 μM, 10 μM Tc53 or solv-
ent. Cells were incubated for 2 h/6 h/30 h with Tc52
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before exchange of medium against standard medium.
After a total incubation of 30 h, cells were fixed and
SAβGal-activity assay was performed. To analyze signal
intensity, bright-field photomicrographs were taken with
fixed exposure time using Nikon EclipseTS100 micro-
scope and gray-values were measured with ImageJv1.47n-
software. Nuclei were counted to normalize for cell
number, and gray-values/cell were calculated.
Western blotting
Cells were seeded on 10 cm-dishes and incubated for
24 h. Medium was replaced with medium containing re-
spective toxins and incubated for the indicated times.
After 2 h and 6 h medium was exchanged in the respect-
ive samples against fresh standard medium. After 30 h
incubation of all samples, medium was removed and
floating cells were harvested by centrifugation. Pelleted
cells and cells on the dish were lysed in 95 °C Laemmli-
buffer and combined. Equal volumes were run on SDS-
gels and blotted onto nitrocellulose- (PARP1 detection)
or PVDF-membrane. Membranes were blocked with
TBS/0.1 % Tween20/3 % BSA/10 % non-fat dry-milk for
2 h at 37 °C and incubated overnight at 4 °C with 1.anti-
body diluted in TBS/0.1 % Tween20/3 % BSA. Mem-
branes were washed thrice for 20 min at RT in TBS/
0.1 % Tween20/3 % non-fat dry-milk and incubated for 1 h
at RT with 2.antibody in TBS/0.1 % Tween20/3 % non-fat
dry-milk. After three washes in TBS/0.1 % Tween20, ECL
detection was performed (Pierce ECL-SuperSignal-Femto,
ThermoFisher Scientific). Antibodies: rabbit-polyclonal
anti-GAPDH (Ambion); mouse-monoclonal anti-actin
(Millipore); rabbit-polyclonal anti-p38 kinase, rabbit-
monoclonal anti-phospho-p38 kinase, rabbit-polyclonal
anti-tubulin, mouse-monoclonal anti-cleaved caspase7
(Cell-Signaling); goat-anti-rabbit IgG-HRP, goat-anti-mouse
IgG-HRP (Sigma), mouse-monoclonal anti-PARP1 C-2-10
(SantaCruz-Biotechnologies).
Statistics
All experiments were performed at least three times in-
dependently. Statistics were calculated using GraphPad-
Prism5 software and tests suggested by the program
were used. Presented are means +/− SEM.
Abbreviations
Col, colcemid; CytB, cytochalasin B; DAPI, 4',6-diamidino-2-
phenylindole; Doc, docetaxel; FADU, Fluorometric Analysis
of DNA Unwinding; MI, mitotic index; MMC, mitomycin
C; PAR, poly(ADP-ribose); PARP1, poly(ADP-ribose)poly-
merase1; p-p38, phosphorylated p38 stress-kinase; RT, room
temperature; SAHF, senescence-associated heterochromatic
foci; SAβGal, senescence-associated beta-galactosidase
Additional files
Additional file 1: Structure of Tc52 and Tc53. Top structure highlights
the identical backbone of Tc52 and Tc53. R (circled in red) indicates the
two different side-chains of Tc52 (methyl-group) and Tc53 (tert-butyl-
group), respectively. Depicted below are the separate structures for Tc52
and Tc53. (PDF 1085 kb)
Additional file 2: Cell viability assay with HeLa tumor cells (squares) and
VH7 normal fibroblasts (circles). Cells were exposed to increasing
concentrations of Tc52 (filled) or Tc53 (open) titanium(IV)salan
compounds solubilized in DMSO and incubated for 48 h. Subsequently,
medium was replaced by fresh medium containing 9 μg/ml resazurin
and cells were further incubated. Viability is expressed as % of solvent
control. Whereas Tc53 is non-toxic in the tested concentration range,
Tc52 impairs viability in HeLa and VH7 cells with an EC20 of 3 μM and 1
μM, an EC50 of 6 μM and 3 μM, respectively, and an EC80 of about 10
μM for both. (PDF 1085 kb)
Additional file 3: Detection of DNA strand break markers poly(ADP-
ribosyl)ation and γH2AX in HeLa and VH7. A: PAR can be weakly
detected in HeLa cells about 5 min after application of 500 μM H2O2 in
cell culture medium, peaking at 10 min, and signals disappear completely
after 60 min. Later time points are not depicted. Phosphorylated H2AX
appears after 10 min incubation as a pan-nuclear signal, with pronounced
characteristic foci formation after 6 h. B: PAR can be weakly detected in
VH7 cells about 5 min after application of 500 μM H2O2 in cell culture
medium, peaking at 30 min and signals disappear completely after 60
min. Later time points are not depicted. Phosphorylated H2AX appears
after 10 min incubation as a pan-nuclear signal, with less well pro-
nounced characteristic foci formation after 60 min. C: H2AX and-tubulin
detection in a time-course from 0 min (Ctr) to 1440 min (24 h) after
application of 500 μM H2O2 (H), 10 μM Tc52 (52) or 10 μM Tc53 (53) to
HeLa cells. Signal-ratio evaluation of γH2AX/tubulin is presented in the
lower panel. γH2AX formation in H2O2 treated samples is evident after
30 min and increases over time. Only after 24 h of Tc52 treatment, a mild
increase in γH2AX is detectable, concurrent with the onset of cell death
(Fig. 1a). (PDF 1085 kb)
Additional file 4: Cell cycle distribution profile of HeLa cells after
continuous Tc52 treatment. Representative histograms from data
presented in Fig. 2. A: Cell-cycle distribution after 30 h of continuous
treatment of cells with 1-10 μM Tc52 (concentration range showing an
effect). Note the small (not significant) reduction in G1 with 2 μM Tc52
and the strong reduction with 5 μM and 10 μM Tc52 concomitant with a
substantial increase in the subG1 fraction. The sample treated with 5 μM
Tc52 displays in addition an increased number of cells in G2, whereas
cells treated with 10 μM show a reduction in G2 phase. B: Cell-cycle
distribution after 48 h of continuous treatment of cells with 1-10 μM
Tc52 (concentration range showing an effect). Note the reduction in G1
with 1-2 μM Tc52 and the nearly complete loss in samples treated with 5
μM and 10 μM Tc52. SubG1 is increased in all samples and cells treated
with 1 μM Tc52 display a significant increase in G2 phase. (PDF 1085 kb)
Additional file 5: Cell cycle distribution profile of HeLa cells after
treatment with M-phase targeting toxins in combination with Tc52.
Representative flow-cytometry histograms from data presented in Fig. 3.
For better visibility, only one M-phase targeting toxin with or without 6
μM Tc52 is displayed in each panel. There is no significant difference in
cell-cycle profiles of Tc52 or control samples except a small increase G2-
phase in Tc52 treated cells (upper left panel). CytB-treated samples show
a near-complete loss of G1-peak and a reduction in G2, concomitant with
an increase in subG1 and the appearance of a substantial cell-fraction
with a >4 N DNA content with a strong peak at about 8 N (compare
black graphs from upper right and upper left panel). Combination with
Tc52 reduces this 8 N peak and increases the number of cells in G2 and
slightly the number of cells in G1 (upper right panel). Col-treatment
induces a reduction in G1-phase (compare the black graphs from lower
left and upper left panel) concomitant with an increase in G2 and subG1
(lower left panel). Combination with Tc52 does not change the cell-cycle
profile significantly. 50 nM Doc induces a complete loss of cells from G1,
concomitant with an increase in subG1 fraction, number of cells in G2 as
wells as cells with a > 4 N DNA content (compare black graphs from
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lower right panel with upper left panel). Addition of Tc52 decreased the
number of cells with a > 4 N DNA content (lower right panel).
(PDF 1085 kb)
Additional file 6: Cell cycle distribution profile of cells after 6 h of treatment.
Representative flow-cytometry histograms from data presented in Fig. 4. For
better visibility, surface of the graph from Ctr sample (black line) is dotted. A:
Cell-cycle distribution of HeLa cells after 6 h incubation with Titanium(IV)salan
complexes Tc52 and Tc53 30 h after treatment start. Only 10 μM Tc52 shows
significant impact on cell-cycle profile, i.e. severe reduction in G1 and increase
of the subG1 fraction. B: Cell-cycle distribution of VH7 normal fibroblasts after 6
h incubation with Titanium(IV)salan complexes Tc52 and Tc53 30 h after
treatment start. Samples exposed to 5 μM and 10 μM Tc52 display major
reduction in number of cells in G1 concomitant with a mild increase in
G2-phase. SubG1 fraction is not significantly elevated. (PDF 1086 kb)
Additional file 7: Analysis of rapid free cytosolic Ca2 + -shifts in HeLa
tumor cells and VH7 normal fibroblasts. Cells were processed as suggested
by the manufacturer. Tc52 or Tc53 or solvent control (CTR) was
administered to the cells and Ca2 + -dependent increase in fluorescence of
Fluo4-NW-dye was measured. Significant increase in fluorescence is an
indicator for cell death signaling. A: Increase in free cytosolic Ca2+ in HeLa
cells. Both concentrations show significant and rapid increase in Ca2+ signal,
reaching after 5 sec 4 and 5.5 RFU above CTR and after 10 sec 6.5 and 5
RFU above CTR, whereas control and Tc53 values stay low. B: No significant
increase in free cytosolic Ca2+ in VH7 cells. Only the 10 μM Tc52 exposure
samples display initially a mild increase (1 RFU above CTR), which is lost after
10 sec (0 RFU above CTR). As summary, rapid Ca2+ increase is indicative for
cytotoxicity of Tc52 in HeLa cells, whereas its toxicity is negligible in VH7
normal fibroblasts, in line with other data. (PDF 1085 kb)
Additional file 8: Additional Methods. (PDF 144 kb)
Additional file 9: Analysis of p38 kinase and caspase activation by Tc53 in
HeLa and VH7 cells. Cells were exposed to 10 μM Tc53 or solvent for 30 h
and subsequently lysed in Laemmli buffer. Western blot analysis was
performed as described for Figs. 6 and 7. There is no evidence for activation
of p38 in. HeLa or VH7 cells (A) or cleavage of caspase7 (B). Significance was
tested using two-tailed T-test. Panel (C) depicts the respective western blot
for cleaved caspase7 (cleaved Casp7), GAPDH, total p38 stresskinase (p38),
phosphorylated p38 (p-p38) and αtubulin (Tubulin). +: positive control, C:
solvent control samples, T: 10 μM Tc53 treated samples. Numbers indicate
respective independent experiments. (PDF 1085 kb)
Additional file 10: Cell viability assay with U2OS tumor cells (squares) and
low-passage HEK293 (circles). Cells were exposed to increasing concentrations
of Tc52 (filled) or Tc53 (open) titanium(IV)salan compounds solubilized in
DMSO and incubated for 48h. Subsequently, medium was replaced by fresh
medium containing 9 μg/ml resazurin and cells were further incubated.
Viability is expressed as % of solvent control. Whereas Tc53 is non-toxic in the
tested concentration range, Tc52 impairs viability in U2OS and HEK293 cells
with an EC20 of 1.5 μM and 2.5 μM, an EC50 of 2 μM and 4 μM, and an EC80
of about 4 μM and 20 μM, respectively. (PDF 1085 kb)
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